Tuesday, February 8, 2011

Now you have IV Tylenol

U.S. Food and Drug Administration (FDA) has granted marketing approval for IV version of acetaminophen (OFIRMEV) about 3 months ago and will be marketed this year. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever, particularly for postoperative pain.

In clinical studies, OFIRMEV improved pain relief, reduced opioid consumption, and improved patient satisfaction when used as part of a multi-modal regimen. It can be use in adults as well as pediatric patients.

OFIRMEV standard dose is 1000 mg every six hours or 650 mg every four hours. It has an onset of action within 15 minutes after treatment.